Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $92.60

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $93.33.

Several analysts have issued reports on the stock. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Tuesday, March 18th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. Royal Bank of Canada raised their target price on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a report on Friday, March 21st. Finally, Oppenheimer increased their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Kestra Investment Management LLC bought a new position in Prestige Consumer Healthcare in the fourth quarter worth $27,000. CIBC Private Wealth Group LLC increased its stake in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after acquiring an additional 152 shares in the last quarter. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare during the 4th quarter valued at about $40,000. Huntington National Bank boosted its stake in Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after acquiring an additional 181 shares in the last quarter. Finally, McIlrath & Eck LLC grew its holdings in Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock worth $75,000 after purchasing an additional 154 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

PBH opened at $85.04 on Wednesday. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.21 billion, a P/E ratio of 19.92, a PEG ratio of 2.69 and a beta of 0.46. The stock has a 50-day moving average price of $82.86 and a 200-day moving average price of $78.79. Prestige Consumer Healthcare has a 12-month low of $62.35 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.